Human renal cortical and medullary UDP-glucuronosyltransferases (UGTs): Immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 2, 2007, Pages 422-430

  Gaganis, Paraskevi ^a   Miners, John O ^a,b   Brennan, James S ^b   Thomas, Anthony ^a,b   Knights, Kathleen M ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B7; NAPROXEN;

ARTICLE; BOWMAN CAPSULE; CATALYSIS; CONTROLLED STUDY; DRUG ELIMINATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME LOCALIZATION; GLUCURONIDATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; KIDNEY CORTEX; KIDNEY MEDULLA; KIDNEY METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION;

GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY MEDULLA; KINETICS; MALE; NAPROXEN;

EID: 35548996327     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.128603     Document Type: Article

References (41)

1. Barbier O, Lapointe H, El Alfy M, Hum DW, and Belanger A (2000) Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistochemistry. J Clin Endocrinol Metab 85:4819-4826.
2. Bledsoe T, Liddle GW, Riondel A, Island DP, Bloomfield D, and Sinclair-Smith B (1966) Comparative fates of intravenously and orally administered aldosterone: evidence for extrahepatic formation of acid-hydrolyzable conjugate in man. J Clin Invest 45:264-269.
3. Bonvalet JP, Pradelles P, and Farman N (1987) Segmental synthesis and actions of prostaglandins along the nephron. Am J Physiol 253:F377-F387.
4. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, and Miners JO (2005) S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423-433.
5. Bowalgaha K and Miners JO (2001) The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52:605-609.
6. Chowdhury JR, Novikoff PM, Chowdhury NR, and Novikoff AB (1985) Distribution of UDP glucuronosyltransferase in rat tissue. Proc Natl Acad Sci U S A 82:2990-2994.
7. Elmamlouk TH, Mukhtar H, and Bend JR (1981) The nuclear envelope as a site of glucuronyltransferase in rat liver: properties of and effect of inducers on enzyme activity. J Pharmacol Exp Ther 219:27-34.
8. Girard C, Barbier O, Veilleux G, El-Alfy M, and Belanger A (2003) Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. Endocrinology 144:2659-2668.
9. Goldstein RS and Schnellmann RG (1996) Toxic responses of the kidney, in Casarett and Doull's Toxicology: The Basic Science of Poisons (Klaassen CD ed) pp 471-442, McGraw-Hill Companies, New York.
10. Hjelle JT, Hazelton GA, Klaassen CD, and Hjelle JJ (1986) Glucuronidation and sulfation in rabbit kidney. J Pharmacol Exp Ther 236:150-156.
11. Knights KM, Tsoutsikos P, and Miners JO (2005) Novel mechanisms of nonsteroidal anti-inflammatory drug-induced renal toxicity. Expert Opin Drug Metab Toxicol 1:399-408.
12. Kuehl GE, Lampe JW, Potter JD, and Bigler J (2005) Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 33:1027-1035.
13. Little JM, Kurkela M, Sonka J, Jantti S, Ketola R, Bratton S, Finel M, and Radominska-Pandya A (2004) Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP- glucuronosyltransferases. J Lipid Res 45:1694-1703.
14. Lohr JW, Wilsky GR, and Acara MA (1998) Renal drug metabolism. Pharmacol Rev 50:107-141.
15. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
16. McGurk KA, Brierley CH, and Burchell B (1998) Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochem Pharmacol 55:1005-1012.
17. Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347-369.
18. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application if in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
19. Murray GI and Burke MD (1995) Immunohistochemistry of drug-metabolizing enzymes. Biochem Pharmacol 50:895-903.
20. Murray MD and Brater DC (1993) Renal toxicity of the nonsteroidal antiinflammatory drugs. Annu Rev Pharmacol Toxicol 32:435-465.
21. Okonogi H, Nishimura M, Utsunomiya Y, Hamaguchi K, Tsuchida H, Miura Y, Suzuki S, Kawamura T, Hosoya T, and Yamada K (2001) Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol 55:357-364.
22. Olyaei AJ, Demattos AM, and Bennett WM (2003) Drug dosage in renal failure, in Clinical Nephrotoxins, 2nd ed (De Broe ME, Porter GA, Bennett WM, and Verpooten GA eds) pp 667-679, Kluwer Academic Publishers, Dordrecht, The Netherlands.
23. Peters WH, Allebes WA, Jansen PL, Poels LG, and Capel PJ (1987) Characterization and tissue specificity of a monoclonal antibody against human uridine 5′-diphosphate-glucuronosyltransferase. Gastroenterology 93:162-169.
24. Radominska-Pandya A, Pokrovskaya ID, Xu J, Little JM, Jude AR, Kurten RC, and Czernik PJ (2002) Nuclear UDP-glucuronosyltransferases: identification of UGT2B7 and UGT1A6 in human liver nuclear membranes. Arch Biochem Biophys 399:37-48.
25. Runkel R, Chaplin MD, Sevelius H, Ortega E, and Segre E (1976) Pharmacokinetics of naproxen overdoses. Clin Pharmacol Ther 20:269-277.
26. Rush GF and Hook JB (1984) Characteristics of renal UDP- glucuronyltransferase. Life Sci 35:145-153.
27. Saarikoski ST, Wikman HA, Smith G, Wolff CH, and Husgafvel-Pursiainen K (2005) Localization of cytochrome P450 CYP2S1 expression in human tissues by in situ hybridization and immunohistochemistry. J Histochem Cytochem 53:549-556.
28. Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, and King C (2004) Glucuronidation of carboxylic acid containing compounds by UDP- glucuronosyltransferase isoforms. Arch Biochem Biophys 424:219-225.
29. Saker BM (2000) Everyday drug therapies affecting the kidneys. Aust Presc 23:17-19.
30. Schaaf GJ, de Groene EM, Maas RF, Commandeur JN, and Fink-Gremmels J (2001) Characterization of biotransformation enzyme activities in primary rat proximal tubular cells. Chem Biol Interact 134:167-190.
31. Soars MG, Riley RJ, Findlay KA, Coffey MJ, and Burchell B (2001) Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Dispos 29:121-126.
32. Spahn-Langguth H and Benet LZ (1992) Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24:5-48.
33. Sutherland L, Ebner T, and Burchell B (1993) The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol 45:295-301.
34. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, and Knights KM (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191-199.
35. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
36. Uchaipichat V, Mackenzie PI, Guo X-H, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
37. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, and Miners JO (2006) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
38. Upton RA, Buskin JN, Williams RL, Holford NH, and Riegelman S (1980) Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine. J Pharm Sci 69:1254-1257.
39. Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP, Vree JB, and Guelen PJ (1993) Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Biopharm Drug Dispos 14:491-502.
40. Whelton A, Sturmer T, and Porter GA (2003) Non-steroidal anti-inflammatory drugs, in Clinical Nephrotoxins, 2nd ed (De Broe ME, Porter GA, Bennett WM, and Verpooten GA eds) pp 279-306, Kluwer Academic Publishers, Dordrecht, The Netherlands.
41. Yue Q, Odar-Cederlof I, Svensson JO, and Sawe J (1988) Glucuronidation of morphine in human kidney microsomes. Pharmacol Toxicol 63:337-341.